Five Prime Therapeutics (FPRX) Getting Favorable Media Coverage, Report Finds
Media headlines about Five Prime Therapeutics (NASDAQ:FPRX) have been trending positive recently, AlphaOne Sentiment Analysis reports. AlphaOne, a service of Accern, identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Five Prime Therapeutics earned a media sentiment score of 0.33 on AlphaOne’s scale. AlphaOne also gave media coverage about the biotechnology company an impact score of 82 out of 100, meaning that recent press coverage is very likely to have an impact on the stock’s share price in the near term.
These are some of the headlines that may have impacted AlphaOne Sentiment Analysis’s rankings:
- Five Prime Therapeutics to Announce First Quarter 2017 Financial Results and Host Conference Call on May 4 – Nasdaq (nasdaq.com)
- Five Prime to Present Clinical Data at 2017 ASCO Annual Meeting (finance.yahoo.com)
- Positive News Coverage Extremely Likely to Effect Five Prime Therapeutics (FPRX) Stock Price (americanbankingnews.com)
Five Prime Therapeutics (NASDAQ:FPRX) traded up 1.95% on Friday, hitting $32.99. 473,876 shares of the stock traded hands. The stock’s market cap is $907.52 million. The stock has a 50-day moving average price of $36.91 and a 200 day moving average price of $46.94. Five Prime Therapeutics has a 12-month low of $31.79 and a 12-month high of $60.98.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings data on Thursday, February 23rd. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.57) by $0.16. The firm had revenue of $8.30 million for the quarter, compared to analyst estimates of $7.09 million. Five Prime Therapeutics had a net margin of 64.94% and a return on equity of 59.23%. The firm’s revenue for the quarter was down 97.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $10.63 EPS. On average, equities analysts expect that Five Prime Therapeutics will post ($4.26) EPS for the current fiscal year.
FPRX has been the topic of several analyst reports. Instinet initiated coverage on shares of Five Prime Therapeutics in a research note on Wednesday, March 1st. They issued a “buy” rating and a $94.00 price target on the stock. Nomura initiated coverage on shares of Five Prime Therapeutics in a research note on Wednesday, March 1st. They issued a “buy” rating on the stock. TheStreet lowered shares of Five Prime Therapeutics from a “c” rating to a “d+” rating in a research note on Monday, March 20th. Finally, Cowen and Company initiated coverage on shares of Five Prime Therapeutics in a research note on Friday, March 24th. They issued an “outperform” rating on the stock. Eight analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $63.17.
ILLEGAL ACTIVITY WARNING: “Five Prime Therapeutics (FPRX) Getting Favorable Media Coverage, Report Finds” was first posted by Financial Market News and is the property of of Financial Market News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.financial-market-news.com/2017/04/21/five-prime-therapeutics-fprx-getting-favorable-media-coverage-report-finds.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.